TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib
TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib is a paper indexed in PICO Portal from OpenAlex.
How many citations does TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib have?
TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib has 69 citations in the OpenAlex counts PICO Portal stores.
When was TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib published?
TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib has 2018 year in the PICO Portal index.
What is the open-access status of TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib?
TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib has diamond oa status in the PICO Portal index.
What is the DOI of TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib?
The DOI for TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib is on the source record.
What is the PMID of TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib?
The PMID for TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib is on the source record.
What is the OpenAlex record for TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib?
The OpenAlex for TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib is on the source record.